View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 24, 2021

Genevant and Takeda to develop gene therapies for liver diseases

Genevant’s lipid nanoparticle technology will be leveraged by Takeda to create novel nonviral gene therapies.

Genevant Sciences has signed an international partnership and license agreement with Takeda Pharmaceutical to develop and market new nonviral gene therapies for the treatment of up to two undisclosed rare liver diseases.

Genevant will be eligible for up to $303m upfront, as well as potential milestone payments, apart from royalties on future sales of the products developed through the alliance.

Takeda will hold exclusive rights to use Genevant’s lipid nanoparticle (LNP) technology to develop and market specified nonviral gene therapies for up to two rare liver diseases.

Takeda Pharmaceutical liver disease research head Bernard Allan said: “Building on our existing foundation with Genevant in liver fibrosis, we’re excited to expand our work together to develop life-altering, nonviral gene therapies for specified rare liver diseases.

“Genevant’s expertise in the development of LNPs for clinical applications, coupled with Takeda’s drug development capabilities and history in gastroenterology, gives us a great opportunity to develop new treatment options for patients with liver disorders.”

The latest alliance is the second partnership between the companies.

In March this year, Genevant and Takeda entered an agreement to develop nucleic acid treatments directed to select targets in hepatic stellate cells for the treatment of liver fibrosis by leveraging the former’s LNP technology.

According to the previous deal, Genevant is eligible to get upfront and milestone payments of up to $600m, as well as sales royalties.

Genevant Sciences president and CEO Pete Lutwyche said: “LNP provides a compelling approach to deliver on the promise of gene therapy, and our leadership position in the LNP space is well established.

“We have enjoyed working with our Takeda colleagues to develop hepatic stellate cell-directed treatments to treat liver fibrosis and are delighted to expand the relationship further with this second collaboration.”

Last month, Takeda partnered with Frazier Healthcare Partners to launch a biopharmaceutical company named HilleVax to develop and market its norovirus vaccine candidate, HIL-214 (previously TAK-214).

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology